Editor's Note
In a June 19 letter to healthcare providers, the Food & Drug Administration (FDA) says it continues to evaluate information from several sources, including manufacturers, on the risks associated with Type III endoleaks with various endovascular graft systems used for treatment of abdominal aortic aneurysms (AAAs) and aorto-iliac aneurysms.
Based on new information, the FDA says the Endologix AFX with Strata device is at greater risk for Type III endoleaks than other endovascular AAA graft systems.
Remote surgery has come a long way since the first-ever…
Takeaways • US surgeons have no mandated retirement age. According…
Imagine completely eliminating surgical site infections (SSIs) without significantly disrupting…